Teva says patent use was ‘legitimate’ in court appeal against EU’s Copaxone drug fine
MLex Summary: Teva Pharmaceuticals has said it believes the European Commission misconstrued the patent system when fining the company last year for an antitrust abuse related to a multiple sclerosis drug. In...To view the full article, register now.
Already a subscriber? Click here to view full article